TTI-101 is under clinical development by Tvardi Therapeutics and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase I drugs for Metastatic Hepatocellular Carcinoma (HCC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TTI-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TTI-101 overview

TTI-101 is under development for the treatment of unspecified cancers, solid tumors including breast cancer, metastatic hormone receptor-positive and HER2-negative breast cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, metastatic hepatocellular carcinoma, colorectal cancer, gastric adenocarcinoma and melanoma, cachexia, skin, liver, inflammation, idiopathic pulmonary fibrosis, scleroderma. It is administered intravenously and orally (in the form of hard capsule). The drug candidate act by targeting signal transducer and activator of transcription (STAT) 1 and 3. It was also under development for the treatment of inflammatory bowel disease. 

Tvardi Therapeutics overview

Tvardi Therapeutics., is a biotechnology company that developing a new class of breakthrough medicines for diverse cancers. The company is headquartered in United States.

For a complete picture of TTI-101’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.